During the "Lightning Round" segment of Mad Money Thursday night, one caller asked Jim Cramer about Cardlytics (CDLX) : "This looks like the right price to buy into this one," said Cramer.
More from Investing
Investors have the opportunity to buy Bristol-Myers Squibb at a fairly low valuation, along with a solid 2.8% dividend yield.
I try hard to not rush to be bearish, but I'm seeing some reasons for caution, and here they are.
Penny stocks are for suckers, and six other rules for better investing -- and tuning out the tweet noise.